Genetic Interaction Between NRAS and BRAF Mutations and PTEN/MMAC1 Inactivation in Melanoma
|
|
- Hector Parsons
- 5 years ago
- Views:
Transcription
1 Genetic Interaction Between NRAS and BRAF Mutations and PTEN/MMAC1 Inactivation in Melanoma Hensin Tsao, 1 Vikas Goel, 1 Heng Wu, Guang Yang, and Frank G. Haluska Wellman Laboratories, Department of Dermatology, Division of Oncology, Department of Medicine, Massachusetts General Hospital Melanoma Center, Massachusetts General Hospital, Boston, Massachusetts, USA Extant evidence implicates growth factor signaling in the pathogenesis of many tumor types, including cutaneous melanoma. Recently, reciprocal activating mutations of NRAS and BRAF were found in benign melanocytic nevi and cutaneous melanomas. We had previously reported a similar epistatic relationship between activating NRAS mutations and inactivating PTEN/MMAC1 alterations. We thus hypothesized that BRAF and PTEN/MMAC1 mutations may cooperate to promote melanoma tumorigenesis. Overall, 40 of 47 (85%) melanoma cell lines and 11 of 16 (69%) uncultured melanoma metastases had mutations in NRAS, BRAF, or PTEN/MMAC1. NRAS was exclusively mutated in nine of 47 (19%) cell lines and two of 16 (13%) metastases, whereas BRAF was solely mutated in 28 of 47 (60%) cell lines and nine of 16 (56%) metastases. In the 12 of 15 melanoma cell lines (80%) and two of two melanoma metastases with PTEN alterations, BRAF was also mutated. These findings suggest the existence of possible cooperation between BRAF activation and PTEN loss in melanoma development. Key words: BRAF/melanoma/NRAS/PTEN. J Invest Dermatol 122: , 2004 Sustained growth factor signaling is a critical step in the evolution of cutaneous melanoma. In vitro, basic fibroblast growth factor can form an autocrine stimulatory loop (Meier et al, 2000; Graeven et al, 2001), whereas in vivo, transgenic expression of the receptor tyrosine kinase, RET (Iwamoto et al, 1991; Kato et al, 1998), leads to melanocytic tumors. Post-receptor, activating RAS mutations have also been reported in a significant proportion of cutaneous melanomas (Herlyn and Satyamoorthy, 1996; van Elsas et al, 1996). Two distinct RAS signaling streams the RAS/RAF/MAPK and the RAS/PI3-K/PTEN/AKT pathways have both been shown to be activated in primary melanomas (Cohen et al, 2002; Dhawan et al, 2002; Govindarajan et al, 2003; Satyamoorthy et al, 2003). Moreover, BRAF, which is a component of the RAS/RAF/MAPK signaling cassette, was recently found to be mutated in 60% to 80% of cutaneous melanomas and benign melanocytic nevi (Davies et al, 2002; Pollock et al, 2003). Taken together, the RAS signaling network represents a rich source of oncogenic events. We had previously demonstrated a reciprocal relationship between NRAS activation and PTEN/MMAC1 inactivation in melanoma cell lines and uncultured specimens (Tsao et al, 2000). As RAS directly stimulates PI3-K (Rodriguez-Viciana et al, 1996, 1997) and PTEN attenuates PI3-K signaling (Maehama and Dixon, 1998; Wu et al, 1998), reciprocal NRAS and PTEN/MMAC1 alterations may contribute to the heightened AKT activity observed in melanomas (Dhawan et al, 2002). As loss of PTEN protein expression occurs in 63% of primary melanomas and only 8% of nevi (Tsao et al, 2003), 1 These authors contributed equally to the work. inactivation of PTEN/MMAC1 may be a feature of progression from melanocytic nevi to primary melanoma. Likewise, a similar epistatic relationship between oncogenic alleles of NRAS and BRAF has also been described (Davies et al, 2002; Pollock et al, 2003). As RAS activates RAF leading to MAPK stimulation (Campbell et al, 1998), reciprocal NRAS and BRAF mutations may account for the increased MAPK activity reported for melanoma (Cohen et al, 2002; Govindarajan et al, 2003; Satyamoorthy et al, 2003). The genetic relationship described for NRAS, BRAF, and PTEN/MMAC1 raises the possibility that BRAF activation and PTEN/MMAC1 inactivation cooperate to simulate NRAS activation in order to promote melanoma tumorigenesis. To test this hypothesis directly, we screened for BRAF mutations in a series of melanoma samples whose NRAS and PTEN/MMAC1 had been previously characterized and found evidence for possible cooperation between BRAF and PTEN/MMAC1. Results and Discussion Using PCR single strand conformation polymorphism, we evaluated 47 melanoma cell lines and 16 uncultured metastatic melanoma specimens for mutations in exons 11 and 15 of BRAF. Whereas no exon 11 amplicons exhibited altered migration, multiple exon 15 amplicons demonstrated mobility shifts suggestive of sequence variants (Fig 1a). After direct sequencing, we found that 28 of 47 (62%) melanoma lines harbored mutations at valine lines had the canonical T1796A (BRAF V599E ) mutation, whereas two lines harbored the TG AT Copyright r 2004 by The Society for Investigative Dermatology, Inc. 337
2 338 TSAO ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY Figure 1 (A) PCR single strand conformation polymorphism. Analysis of BRAF exon 15. Amplified exon 15 fragments containing the normal (V599) and mutant (E599) variants exhibit differential mobilities, as indicated by the upper and lower arrows, respectively. The asterisk marks the presence of the mutant allele. Note that the cell line in lane 3 is homozygous for the E599 mutation (lane 1: Mel-Swift; lane 2: MGH-BO-1; lane 3: SK-Mel 28; lane 4: WM455; lane 5: SK-Mel 63). (B) BRAF genotypes showing loss of normal allele at codon 599. (BRAF V599D ) mutation. The BRAF V599E mutation was also present in nine of 16 (56%) uncultured metastatic melanoma specimens. In three of 28 melanoma cell lines with BRAF V599 mutations, the normal BRAF allele was deleted (Fig 1a,b). Although loss of heterozygosity is typically a signature of a tumor suppressor locus, shedding of the wild-type allele has been described for NRAS (Osaka et al, 1997), KRAS (Sukumar et al, 1991), and HRAS (Saranath et al, 1991). As the BRAF V599 alterations are presumably gain-of-function mutations, the normal allele would represent a hypofunctional competitor whose loss could potentiate the effectiveness of the BRAF V599 variant. Alternatively, Diaz et al (2002), recently found that the presence of a wild-type NRAS allele impedes the formation of murine lymphomas in vivo and suppresses the malignant phenotype in vitro; thus, it is conceivable that the BRAF proto-oncogene may exhibit tumor suppressive properties under certain biologic contexts. The NRAS, BRAF, and PTEN/MMAC1 status for the various cell lines and specimens are shown in Tables I and II. Overall, 40 of 47 (85%) melanoma cell lines and 11 of 16 (69%) uncultured melanoma metastases had mutations in at least one of the three loci. Several observations emerged from our analysis. First, NRAS was solely mutated in nine melanoma cell lines and two uncultured melanoma specimens, although there was one additional cell line that exhibited concurrent NRAS and PTEN/MMAC1 alterations (i.e., HS944; Tsao et al, 2000). Second, 15 cell lines and two uncultured metastases exhibited either PTEN/MMAC1 mutations (11 lines, both metastases) or loss of protein expression (four lines, Table I); epigenetic silencing of PTEN/ MMAC1 has been reported in cutaneous melanoma (Zhou et al, 2000). Of the 63 samples analyzed, BRAF was mutated in 12 of 15 (80%) and two of two (100%) of the PTEN-deficient lines and metastatic specimens, respectively (p ¼ 0.02, two-tailed Fisher exact test). An additional 16 melanoma lines and seven uncultured metastases displayed BRAF mutations without either NRAS or PTEN/ MMAC1 participation. Finally, two melanoma lines showed PTEN/MMAC1 inactivation without BRAF involvement. We report, for the first time that, in a subset of melanomas, BRAF activation accompanies PTEN/MMAC1 inactivation to the mutual exclusion of NRAS mutations. These results suggest that (1) BRAF and PTEN/MMAC1 operate on distinct genetic pathways and could cooperate to promote melanoma tumorigenesis, and (2) a single NRAS mutation, albeit not as common as alterations in either BRAF or PTEN/MMAC1, may be sufficient (model shown in Fig 2). As BRAF and PTEN selectively impact the MAPK and AKT pathways, respectively, activation of both signaling streams may be required for melanoma progression. Cohen et al (2002), found that over 80% of primary cutaneous melanomas, but only 20% of benign nevi, expressed active phosphomapk. Satyamoorthy et al (2003), also reported that vertical growth phase and metastatic melanomas, but not benign nevi, stained intensely for active phosphoerk and that the ERK phosphorylation in melanoma cell lines was abrogated by the MEK inhibitor PD With respect to the AKT pathway, Dhawan et al (2002), found increased staining for active phosphoakt in metastatic melanoma specimens but not benign nevi and observed loss of AKT phosphorylation in melanoma cell lines exposed to PI3-K inhibitors, LY and wortmannin. These data, along with our findings, point to an essential role for ongoing trophic signaling, through both MAPK and AKT pathways. The high rate of BRAF mutations in nevi (Pollock et al, 2003; Uribe et al, 2003) implies that the MAPK pathway is genetically engaged early in melanocytic tumor formation but is insufficient to induce full malignant transformation; other events are clearly necessary for progression. We recently found that 19 of 30 (63%) primary melanomas demonstrated significant decreases in PTEN levels, although only three of 39 melanocytic nevi (8%) exhibited loss of PTEN expression (Tsao et al, 2003); these results parallel other observations that active phosphoakt can be detected in melanomas but not in melanocytic nevi (Dhawan et al, 2002). Thus, unlike BRAF activation, PTEN loss appears to be more specific for melanoma tumorigenesis. Taken together, one hypothesis that emerges is that loss of PTEN cooperates with activation of BRAF in the transition from nevus to melanoma. The high BRAF mutation rate, especially in melanoma, raises the possibility of an effective anti-braf therapy. As
3 122 : 2 FEBRUARY 2004 BRAF AND PTEN/MMAC1 COOPERATE IN MELANOMA 339 Cell line Table I. BRAF, NRAS, and PTEN/MMAC1 mutations in melanoma cell lines NRAS a PTEN/MMAC1 BRAF exon 15 Mutation Effect Mutation Effect Mutation Effect MGH-MC-2 G35A G12D wt WT wt WT Mel-Swift C180A Q61K wt WT wt WT MGH-PO-1 C180A Q61K wt WT wt WT SK Mel-l19 A181G Q61R wt WT wt WT SK Mel-30 C180A Q61K wt WT wt WT Mel Juso A181T Q61L wt WT wt WT K19 C180A Q61K wt WT wt WT HS940 A181G Q61R wt WT wt WT SK Mel 63 C180A Q61K wt WT wt WT HS944 C180A Q61K Del exon2 Frameshift/premature stop wt WT SK Mel 39 wt WT 546insA Frameshift/premature stop T1796A V599E MGH-BO-1 wt WT Del exon2 Frameshift/premature stop T1796A V599E Sk Mel37 wt WT Del exon 2 Frameshift/premature stop T1796A V599E UACC 903 wt WT T226G Tyr 76 Stop T1796A V599E RU wt WT IVS3del þ 1! þ4 Possible splice variant T1796A V599E MM455 wt WT Del exon 6 Frameshift/premature stop T1796A V599E SK Mel 28 wt WT A499G T167A T1796A b 599E SK Mel 131 wt WT IVS5 þ 2T! A Possible splice variant T1796A V599E MEL-11 wt WT wt No protein c T1796A V599E WM1158 wt WT wt No protein c T1796A V599E WM239A wt WT wt No protein c TG AT V599D WM1799 wt WT Failed PCR No protein c T1796A V599E SK Mel 23 wt WT Del gene No predicted product wt WT ML wt WT Del gene No predicted product wt WT MGH-MC-1 wt WT wt WT T1796A V599E K1-Mel wt WT wt WT T1796A V599E MEL-31 wt WT wt WT T1796A V599E WM164 wt WT wt WT T1796A V599E MH-12 wt WT wt WT TG AT V599D MH-2 wt WT wt WT T1796A V599E K-16 wt WT wt WT T1796A V599E A375 wt WT wt WT T1796A b 599E HS939T wt WT wt WT T1796A V599E MH-17 wt WT wt WT T1796A V599E Malme wt WT wt WT T1796A V599E K4 wt WT wt WT T1796A V599E Steele wt WT wt WT T1796A V599E K2 wt WT wt WT T1796A V599E WM115 wt WT wt WT T1796A V599E MM608 wt WT wt WT T1796A b 599E a NRAS, PTEN/MMAC1 status on some cell lines published in Tsao et al (2000). b Both alleles show 599E. c No protein by western.
4 340 TSAO ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY Table II. BRAF, NRAS, and PTEN/MMAC1 mutations a in melanoma metastases NRAS PTEN/MMAC1 BRAF Exon 15 Cutaneous melanoma specimens Mutation Effect Mutation Effect Mutation Effect 30 A181G Q61R wt WT wt WT 7 A181G Q61R wt WT wt WT 31 (KM16) wt WT ROH HD T1796A V599E 33 (KM17) wt WT 1591 Dup Frameshift T1796A V599E (nt ) 271 stop 6 wt WT wt WT T1796A V599E 8 wt WT wt WT T1796A V599E 16 wt WT wt WT T1796A V599E 22 wt WT wt WT T1796A V599E 24 wt WT wt WT T1796A V599E 25 wt WT wt WT T1796A V599E 28 wt WT wt WT T1796A V599E 4 wt WT wt WT wt WT 15 wt WT wt WT wt WT 12 wt WT wt WT wt WT 9 wt WT wt WT wt WT 10 wt WT wt WT wt WT a PTEN/MMAC1 andnras genetic status reported in Tsao et al (1998, 2000). ROH: retention of heterozygosity. our data document a significant rate of concurrent mutations in the RAS/PI3-VK/PTEN/AKT pathway, monotherapy targeted at BRAF alone may be ineffectual. Further studies will obviously be necessary in order to optimize rationale drug design. In summary, we have identified a potential genetic interaction between three components of the RAS signaling network NRAS, BRAF, and PTEN/MMAC1. Based on the known cellular functions of these respective gene products, the pattern of mutations suggest that the MAPK and AKT pathways are frequently activated in parallel, by genetic means, to promote melanoma development. Materials and Methods Cell lines and DNA The human melanoma cell lines, culture conditions, uncultured melanoma specimens, and their NRAS and PTEN/MMAC1 status have been described previously (Tsao et al, 2000). All studies were done in accordance with a protocol approved by the IRB at the Massachusetts General Hospital. Polymerase chain reaction (PCR) single strand conformation polymorphism Primer sequences for the exons 11 and 15 of BRAF are published (Davies et al, 2002). Amplification was carried out in 50 ml reaction containing 1 ml of DNA, 1.5 mm MgCl 2 and 40 ng of each primer under standard conditions with or without 0.25 ml of[a 32 P]deoxycytidine triphosphate (NEN, Boston, Massachusetts). The samples were initially denatured at 951C 5 min, than amplified for 35 cycles of 951C 1 min, 621C 1.5 min, 721C 1.5 min, and final extension at 721C for 10 min. The PCR product was confirmed on 1.2% agarose gel. Ten microliters of PCR product was then mixed with 10 ml of the gel loading buffer (95% formamide, 10 mm EDTA, 0.02% bromophenol blue and 0.02% xylene cyanol FF) and the samples were denatured at 951C for 5 min and chilled immediately for 5 min. The sample was loaded on to 6% acrylamide gel containing 10% glycerol, 1 TBE ph 8.0. The gel was run in 0.6 TBE at 5 6 W at 41C for 5 to 6 h. The gel was either stained with a silver staining kit (DNA Silver Staining Kit, Amersham/Pharmacia, Uppsala, Sweden) or exposed to X-ray film (Biomax-MR, Kodak, Rochester, New York), if radioactivity was used. DNA fragments showing mobility shifts were than prepared by PCR under the same condition, purified using Qiaquick PCR purification kit per manufacturer s protocol (Qiagen Inc., Valencia, California) and submitted to Massachusetts General Hospital sequencing core facility for automated sequencing. Western blotting Whole cell lysate was prepared from the melanoma cell lines using RIPA buffer (150 mm NaCl, 50 mm Tris ph 8.0, 1% nonidet P40, 0.1% sodium dodecyl sulfate, 0.5% sodium deoxycholate, 5 mg per ml each of aprotinin and leupeptin and 1 mm of phenylmethylsulfonyl fluoride) containing the cocktail of protease inhibitors (Roche Molecular Biology). Fifty micrograms of protein were loaded on to sodium dodecyl sulfate polyacrylamide gel electrophoresis gel and transferred on to nitrocellulose paper. The blot was incubated with an anti-pten monoclonal antibody at 1:1000 (A2B1, Santa Cruz Biotechnology Inc., Santa Cruz, California). After washing, incubating with secondary antibody (sheep anti-mouse horseradish peroxidase; Amersham
5 122 : 2 FEBRUARY 2004 BRAF AND PTEN/MMAC1 COOPERATE IN MELANOMA 341 Figure 2 Model of various genetic interactions. (A) Normal NRAS stimulates BRAF and PI3-K thereby activating downstream effectors MAPK and AKT, respectively. (B) An NRAS mutation activates both pathways. (C) Activation of BRAF accompanied by concurrent loss of PTEN cooperate to trigger signaling in both pathways. (D) An isolated BRAF mutation unaccompanied by PTEN loss may still engage the AKT signaling through unknown mechanisms. Biosciences, Piscataway, New Jersey), the blot was developed with chemiluminescent substrate. This work was funded in part through grants from the American Cancer Society, Dermatology Foundation, the American Skin Cancer (to H.T.) and the National Institutes of Health (to H.T. and F.G.H.) DOI: /j X x Manuscript received September 17, 2003; revised October 21, 2003; accepted for publication October 28, 2003 Address correspondence to: Hensin Tsao, Wellman Center, Department of Dermatology, Massachusetts General Hospital Melanoma Center, Massachusetts General Hospital, Boston, MA 02114, USA. References Campbell SL, Khosravi-Far R, Rossman KL, Clark GJ, Der CJ: Increasing complexity of Ras signaling. Oncogene 17: , 1998 Cohen C, Zavala-Pompa A, Sequeira JH, et al: Mitogen-activated protein kinase activation is an early event in melanoma progression. Clin Cancer Res 8: , 2002 Davies H, Bignell GR, Cox C, et al: Mutations of the BRAF gene in human cancer. Nature 417: , 2002 Dhawan P, Singh AB, Ellis DL, Richmond A: Constitutive activation of Akt/protein kinase B in melanoma leads to up-regulation of nuclear factor-kappab and tumor progression. Cancer Res 62: , 2002 Diaz R, Ahn D, Lopez-Barcons L, et al: The N-ras proto-oncogene can suppress the malignant phenotype in the presence or absence of its oncogene. Cancer Res 62: , 2002 van Elsas A, Zerp SF, van der Flier S, et al: Relevance of ultraviolet-induced Nras oncogene point mutations in development of primary human cutaneous melanoma. Am J Pathol 149: , 1996 Govindarajan B, Bai X, Cohen C, et al: Malignant transformation of melanocytes to melanoma by constitutive activation of mitogen-activated protein kinase kinase (MAPKK) signaling. J Biol Chem 278: , 2003 Graeven U, Rodeck U, Karpinski S, Jost M, Philippou S, Schmiegel W: Modulation of angiogenesis and tumorigenicity of human melanocytic cells by vascular endothelial growth factor and basic fibroblast growth factor. Cancer Res 61: , 2001 Herlyn M, Satyamoorthy K: Activated ras: Yet another player in melanoma? Am J Pathol 149: , 1996 Iwamoto T, Takahashi M, Ito M, et al: Aberrant melanogenesis and melanocytic tumour development in transgenic mice that carry a metallothionein/ret fusion gene. EMBO J 10: , 1991 Kato M, Takahashi M, Akhand AA, et al: Transgenic mouse model for skin malignant melanoma. Oncogene 17: , 1998 Maehama T, Dixon JE: The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 273: , 1998 Meier F, Nesbit M, Hsu MY, et al: Human melanoma progression in skin reconstructs: Biological significance of bfgf. Am J Pathol 156: , 2000 Osaka M, Matsuo S, Koh T, Sugiyama T: Loss of heterozygosity at the N-ras locus in 7,12-dimethylbenz[a] anthracene-induced rat leukemia. Mol Carcinog 18: , 1997 Pollock PM, Harper UL, Hansen KS, et al: High frequency of BRAF mutations in nevi. Nat Genet 33:19 20, 2003 Rodriguez-Viciana P, Marte BM, Warne PH, Downward J: Phosphatidylinositol 3 0 kinase: One of the effectors of Ras. Philos Trans R Soc London B Biol Sci 351: , discussion , 1996 Rodriguez-Viciana P, Warne PH, Khwaja A, et al: Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras. Cell 89: , 1997 Saranath D, Chang SE, Bhoite LT, et al: High frequency mutation in codons 12 and 61 of H-ras oncogene in chewing tobacco-related human oral carcinoma in India. Br J Cancer 63: , 1991 Satyamoorthy K, Li G, Gerrero MR, et al: Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res 63: , 2003 Sukumar S, Armstrong B, Bruyntjes JP, Leav I, Bosland MC: Frequent activation of the Ki-ras oncogene at codon 12 in N-methyl-N-nitrosourea-induced rat prostate adenocarcinomas and neurogenic sarcomas. Mol Carcinog 4: , 1991 Tsao H, Zhang X, Benoit E, Haluska FG: Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines. Oncogene 16: , 1998 Tsao H, Zhang X, Fowlkes K, Haluska FG: Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines. Cancer Res 60: , 2000 Tsao H, Mihm MC, Sheehan C: PTEN expression in normal skin, acquired melanocytic nevi and cutaneous melanoma. J Am Acad Dermatol 49: , 2003 Uribe P, Wistuba II, Gonzalez S: BRAF mutation: A frequent event in benign, atypical, and malignant melanocytic lesions of the skin. Am J Dermatopathol 25: , 2003 Wu X, Senechal K, Neshat MS, Whang YE, Sawyers CL: The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc Natl Acad Sci USA 95: , 1998 Zhou XP, Gimm O, Hampel H, Niemann T, Walker MJ, Eng C: Epigenetic PTEN silencing in malignant melanomas without PTEN mutation. Am J Pathol 157: , 2000
Osamu Tetsu, MD, PhD Associate Professor Department of Otolaryngology-Head and Neck Surgery School of Medicine, University of California, San
Osamu Tetsu, MD, PhD Associate Professor Department of Otolaryngology-Head and Neck Surgery School of Medicine, University of California, San Francisco Lung Cancer Classification Pathological Classification
More informationPrevalence of Exon 15 BRAF Mutations in Primary Melanoma of the Superficial Spreading, Nodular, Acral, and Lentigo Maligna Subtypes
Prevalence of Exon 15 BRAF Mutations in Primary Melanoma of the Superficial Spreading, Nodular, Acral, and Lentigo Maligna Subtypes Julie Lang and Rona M. MacKie w Duncan Guthrie Institute of Medical Genetics,
More informationReviewers' comments: Reviewer #1 (Remarks to the Author):
Reviewers' comments: Reviewer #1 (Remarks to the Author): In this study the authors analysed 18 deep penetrating nevi for oncogenic genomic changes (single nucleotide variations, insertions/deletions,
More information(A) PCR primers (arrows) designed to distinguish wild type (P1+P2), targeted (P1+P2) and excised (P1+P3)14-
1 Supplemental Figure Legends Figure S1. Mammary tumors of ErbB2 KI mice with 14-3-3σ ablation have elevated ErbB2 transcript levels and cell proliferation (A) PCR primers (arrows) designed to distinguish
More informationChapter 2 Melanoma Pathogenesis
Chapter 2 Melanoma Pathogenesis Jennifer A. Lo and David E. Fisher Abstract Melanoma is an aggressive and heterogeneous disease with respect to clinical behavior and underlying genomic lesions. Melanoma
More informationPersonalized Healthcare Update
Dr. Kai - Oliver Wesche Market Development Manager, Personalized Healthcare QIAGEN Personalized Healthcare Update Pioneering Personalized Medicine through Partnering TOMTOVOK BKM120 Zelboraf QIAGEN partners:
More informationGenetic Testing: When should it be ordered? Julie Schloemer, MD Dermatology
Genetic Testing: When should it be ordered? Julie Schloemer, MD Dermatology Outline Germline testing CDKN2A BRCA2 BAP1 Somatic testing Gene expression profiling (GEP) BRAF Germline vs Somatic testing
More informationUnderstanding Signaling Pathways by Modifying Sensitivity to PLX4720 in B-RAF V600E Melanoma
Understanding Signaling Pathways by Modifying Sensitivity to PLX4720 in B-RAF V600E Melanoma Muska Hassan NCI-ICBP Summer Fellow Broad Institute of MIT and Harvard: Cancer Program Mentor: Cory Johannessen,
More informationPatricia Chevez-Barrrios AAOOP-USCAP /12/2016
Biomarkers in Ocular Melanoma Patricia Chévez-Barrios, MD Pathology and Genomic Medicine, Houston Methodist Hospital Professor of Pathology and Laboratory Medicine and Ophthalmology, Weill Cornell Medical
More informationORIGINAL ARTICLE. Loss of PTEN Expression as a Prognostic Marker for Tongue Cancer
ORIGINAL ARTICLE Loss of PTEN Expression as a Prognostic Marker for Tongue Cancer Janet I. Lee, MD; Jean-Charles Soria, MD; Khaled A. Hassan, MD; Adel K. El-Naggar, MD, PhD; Ximing Tang, MD, PhD; Diane
More informationIdentification of BRAF mutations in melanoma lesions with the Roche z480 instrument
Identification of BRAF mutations in melanoma lesions with the Roche z480 instrument Márta Széll IAP, Siófok May 14, 2012 Multifactorial skin diseses: much more frequent then genodermatoses exhibit familial
More informationRecurrent Patterns of Dual RB and p53 Pathway Inactivation in Melanoma
See related Commentary on page xii Recurrent Patterns of Dual RB and p53 Pathway Inactivation in Melanoma Guang Yang, Anpuchchelvi Rajadurai, and Hensin Tsao w Wellman Center for Photomedicine and wdepartment
More informationAP VP DLP H&E. p-akt DLP
A B AP VP DLP H&E AP AP VP DLP p-akt wild-type prostate PTEN-null prostate Supplementary Fig. 1. Targeted deletion of PTEN in prostate epithelium resulted in HG-PIN in all three lobes. (A) The anatomy
More informationMolecular and genetic analysis of stromal fibroblasts in prostate cancer
Final report ESMO Translational Research Fellowship 2010-2011 Molecular and genetic analysis of stromal fibroblasts in prostate cancer Michalis Karamouzis Host Institute Department of Biological Chemistry,
More informationSUPPLEMENTARY INFORMATION
SUPPLEMENTARY INFORMATION FOR Liver X Receptor α mediates hepatic triglyceride accumulation through upregulation of G0/G1 Switch Gene 2 (G0S2) expression I: SUPPLEMENTARY METHODS II: SUPPLEMENTARY FIGURES
More informationCorporate Medical Policy
Corporate Medical Policy Molecular Analysis for Targeted Therapy for Non-Small Cell Lung File Name: Origination: Last CAP Review: Next CAP Review: Last Review: molecular_analysis_for_targeted_therapy_for_non_small_cell_lung_cancer
More informationBRaf V600E cooperates with Pten silencing to elicit metastatic melanoma (Nature Genetics Supplementary Information)
BRaf V600E cooperates with Pten silencing to elicit metastatic melanoma (Nature Genetics Supplementary Information) David Dankort, David P. Curley, Robert A. Cartlidge, Betsy Nelson, Anthony N. Karnezis,
More informationProtocol for Gene Transfection & Western Blotting
The schedule and the manual of basic techniques for cell culture Advanced Protocol for Gene Transfection & Western Blotting Schedule Day 1 26/07/2008 Transfection Day 3 28/07/2008 Cell lysis Immunoprecipitation
More information7/6/2015. Cancer Related Deaths: United States. Management of NSCLC TODAY. Emerging mutations as predictive biomarkers in lung cancer: Overview
Emerging mutations as predictive biomarkers in lung cancer: Overview Kirtee Raparia, MD Assistant Professor of Pathology Cancer Related Deaths: United States Men Lung and bronchus 28% Prostate 10% Colon
More informationPhospho-AKT Sampler Kit
Phospho-AKT Sampler Kit E 0 5 1 0 0 3 Kits Includes Cat. Quantity Application Reactivity Source Akt (Ab-473) Antibody E021054-1 50μg/50μl IHC, WB Human, Mouse, Rat Rabbit Akt (Phospho-Ser473) Antibody
More informationKRAS: ONE ACTOR, MANY POTENTIAL ROLES IN DIAGNOSIS
UNIVERSITÀ DEGLI STUDI DI PALERMO Scuola di Specializzazione in Biochimica Clinica Direttore Prof. Marcello Ciaccio KRAS: ONE ACTOR, MANY POTENTIAL ROLES IN DIAGNOSIS Loredana Bruno KRAS gene Proto-oncogene
More informationNormal RAS-RAF (MAPK) pathway signaling
BRAF-Mutations in Melanomas L. Mazzucchelli Istituto Cantonale di Patologia, Locarno 77. Annual Meeting Swiss Society of Pathology, Lucerne 2011 Sponsored by Roche Pharma Switzerland Melanoma has increased
More informationResponse and resistance to BRAF inhibitors in melanoma
Response and resistance to BRAF inhibitors in melanoma Keith T. Flaherty, M.D. Massachusetts General Hospital Cancer Center Disclosures Roche/Genentech: consultant GlaxoSmithKline: consultant BRAF mutations
More informationMET skipping mutation, EGFR
New NSCLC biomarkers in clinical research: detection of MET skipping mutation, EGFR T790M, and other important biomarkers Fernando López-Ríos Laboratorio de Dianas Terapéuticas Hospital Universitario HM
More informationMUTATION TEST CE IVD. ctnras-braf FEATURES
ctnras-braf CE IVD TECHNICAL SHEET IDYLLA ctnras-braf MUTATION TEST The Idylla ctnras-braf Mutation Test, performed on the Biocartis Idylla System, is an in vitro diagnostic test for the qualitative detection
More informationWikipedia Article on Epigenetics and Melanoma
Luke Hollifield and Immaculata Ihenacho April 14, 2014 Dr. Atkinson Wikipedia Article on Epigenetics and Melanoma Introduction How and/or why does melanoma occur in people? Melanoma is a rare but aggressive
More informationExamination of Mutations in BRAF, NRAS, and PTEN in Primary Cutaneous Melanoma
ORIGINAL ARTICLE Examination of Mutations in BRAF, NRAS, and PTEN in Primary Cutaneous Melanoma Vikas K. Goel 1,2,5, Alexander J.F. Lazar 2,3,5,6, Carla L. Warneke 4, Mark S. Redston 2,3 and Frank G. Haluska
More informationDifferentiation-induced Changes of Mediterranean Fever Gene (MEFV) Expression in HL-60 Cell
Differentiation-induced Changes of Mediterranean Fever Gene (MEFV) Expression in HL-60 Cell Wenxin Li Department of Biological Sciences Fordham University Abstract MEFV is a human gene that codes for an
More informationSUPPLEMENTARY INFORMATION
Supplementary Figures Supplementary Figure S1. Binding of full-length OGT and deletion mutants to PIP strips (Echelon Biosciences). Supplementary Figure S2. Binding of the OGT (919-1036) fragments with
More informationSupplementary Information Supplementary Fig. 1. Elevated Usp9x in melanoma and NRAS mutant melanoma cells are dependent on NRAS for 3D growth.
Supplementary Information Supplementary Fig. 1. Elevated Usp9x in melanoma and NRAS mutant melanoma cells are dependent on NRAS for 3D growth. a. Immunoblot for Usp9x protein in NRAS mutant melanoma cells
More informationMAPK Pathway. CGH Next Generation Sequencing. Molecular Tools in Care of Patients with Pigmented Lesions 7/20/2017
Molecular Tools in Care of Patients with Pigmented Lesions Tammie Ferringer, MD Geisinger Medical Center, Danville, PA tferringer@geisinger.edu DISCLOSURE OF RELATIONSHIPS WITH INDUSTRY Tammie Ferringer,
More informationThe absence of the ERBB4 hotspot mutations in melanomas in patients from southern China
Brief Report The absence of the ERBB4 hotspot mutations in melanomas in patients from southern China Qi-Ming Zhou 1,2,5*, Wei Li 6*, Yuan-Xiang Guan 1,3, Xing Zhang 1,2, Xin-Chun Chen 6, Ya Ding 1,2, Xi-Zhi
More informationMRC-Holland MLPA. Description version 06; 23 December 2016
SALSA MLPA probemix P417-B2 BAP1 Lot B2-1216. As compared to version B1 (lot B1-0215), two reference probes have been added and two target probes have a minor change in length. The BAP1 (BRCA1 associated
More informationThe Schedule and the Manual of Basic Techniques for Cell Culture
The Schedule and the Manual of Basic Techniques for Cell Culture 1 Materials Calcium Phosphate Transfection Kit: Invitrogen Cat.No.K2780-01 Falcon tube (Cat No.35-2054:12 x 75 mm, 5 ml tube) Cell: 293
More informationNext Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making
Next Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making November 20, 2014 Capturing Value in Next Generation Sequencing Symposium Douglas Johnson MD, MSCI Vanderbilt-Ingram
More informationIslet viability assay and Glucose Stimulated Insulin Secretion assay RT-PCR and Western Blot
Islet viability assay and Glucose Stimulated Insulin Secretion assay Islet cell viability was determined by colorimetric (3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide assay using CellTiter
More informationGenerating Mouse Models of Pancreatic Cancer
Generating Mouse Models of Pancreatic Cancer Aom Isbell http://www2.massgeneral.org/cancerresourceroom/types/gi/index.asp Spring/Summer 1, 2012 Alexandros Tzatsos, MD PhD Bardeesy Lab: Goals and Objectives
More informationHHS Public Access Author manuscript J Invest Dermatol. Author manuscript; available in PMC 2012 June 01.
Deletion of PTENP1 pseudogene in human melanoma Laura Poliseno 1, Adele Haimovic 1, Paul J. Christos 2, Eleazar C. Vega y Saenz de Miera 1, Richard Shapiro 1, Anna Pavlick 1, Russell S. Berman 1, Farbod
More informationGrowth and Differentiation Phosphorylation Sampler Kit
Growth and Differentiation Phosphorylation Sampler Kit E 0 5 1 0 1 4 Kits Includes Cat. Quantity Application Reactivity Source Akt (Phospho-Ser473) E011054-1 50μg/50μl IHC, WB Human, Mouse, Rat Rabbit
More information1.Basis of resistance 2.Mechanisms of resistance 3.How to overcome resistance. 13/10/2017 Sara Redaelli
Dott.ssa Sara Redaelli 13/10/2017 1.Basis of resistance 2.Mechanisms of resistance 3.How to overcome resistance Tumor Heterogeneity: Oncogenic Drivers in NSCLC The Promise of Genotype-Directed Therapy
More informationTHE FUTURE OF IMMUNOTHERAPY IN COLORECTAL CANCER. Prof. Dr. Hans Prenen, MD, PhD Oncology Department University Hospital Antwerp, Belgium
THE FUTURE OF IMMUNOTHERAPY IN COLORECTAL CANCER Prof. Dr. Hans Prenen, MD, PhD Oncology Department University Hospital Antwerp, Belgium DISCLAIMER Please note: The views expressed within this presentation
More informationActivation of cellular proto-oncogenes to oncogenes. How was active Ras identified?
Dominant Acting Oncogenes Eugene E. Marcantonio, M.D. Ph.D. Oncogenes are altered forms of normal cellular genes called proto-oncogenes that are involved in pathways regulating cell growth, differentiation,
More informationOncogenes and Tumor Suppressors MCB 5068 November 12, 2013 Jason Weber
Oncogenes and Tumor Suppressors MCB 5068 November 12, 2013 Jason Weber jweber@dom.wustl.edu Oncogenes & Cancer DNA Tumor Viruses Simian Virus 40 p300 prb p53 Large T Antigen Human Adenovirus p300 E1A
More informationTITLE: CYP1B1 Polymorphism as a Risk Factor for Race-Related Prostate Cancer
AD Award Number: W81XWH-04-1-0579 TITLE: CYP1B1 Polymorphism as a Risk Factor for Race-Related Prostate Cancer PRINCIPAL INVESTIGATOR: Yuichiro Tanaka, Ph.D. CONTRACTING ORGANIZATION: Northern California
More informationConstruction of a hepatocellular carcinoma cell line that stably expresses stathmin with a Ser25 phosphorylation site mutation
Construction of a hepatocellular carcinoma cell line that stably expresses stathmin with a Ser25 phosphorylation site mutation J. Du 1, Z.H. Tao 2, J. Li 2, Y.K. Liu 3 and L. Gan 2 1 Department of Chemistry,
More informationMDJ The Role of K-Ras and PI3Kcb Expression in Oral Vol.:10 No.:2 2013
MDJ The Role of K-Ras and PI3Kcb Expression in Oral Squamous Cell Carcinoma Dr. Asseel Mohammed ghazi. B.D.S Dr.Muna S. Merza. B.D.S, M.Sc. Ph.D Abstract Background: Oral squamous cell carcinoma is an
More informationRAS and RAF Signalling in Melanoma: Biology and Therapies Professor Richard Marais
RAS and RAF Signalling in Melanoma: Molecular Oncology, The Institute of Cancer Research, UK 1 Melanoma Melanocytes are specialised pigment cells - Skin, eyes, ear, brain, heart - Skin/hair tone - Protection
More informationNormal Skin. Tissue Samples and Melanoma Cell Lines. BRAF Mut. RAS Mut RAS WT /BRAF WT
Supplemental Figure 1. MERTK gene expression in melanoma cell line panel from Cancer Cell Line Encyclopedia. A. Microarray analysis of melanoma cell lines from UNC collection grouped by oncogenic mutation.
More informationmirna Dr. S Hosseini-Asl
mirna Dr. S Hosseini-Asl 1 2 MicroRNAs (mirnas) are small noncoding RNAs which enhance the cleavage or translational repression of specific mrna with recognition site(s) in the 3 - untranslated region
More informationSupplementary Online Content
Supplementary Online Content Kris MG, Johnson BE, Berry LD, et al. Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs. JAMA. doi:10.1001/jama.2014.3741 etable 1. Trials
More informationProblem Set 8 Key 1 of 8
7.06 2003 Problem Set 8 Key 1 of 8 7.06 2003 Problem Set 8 Key 1. As a bright MD/PhD, you are interested in questions about the control of cell number in the body. Recently, you've seen three patients
More informationFONS Nové sekvenační technologie vklinickédiagnostice?
FONS 2010 Nové sekvenační technologie vklinickédiagnostice? Sekvenování amplikonů Sequence capture Celogenomové sekvenování FONS 2010 Sekvenování amplikonů Amplicon sequencing - amplicon sequencing enables
More informationHuman Lung Cancer Pathology and Cellular Biology Mouse Lung Tumor Workshop
Human Lung Cancer Pathology and Cellular Biology Mouse Lung Tumor Workshop Jan 7 th and 8 th, 2014 Brigitte Gomperts, MD University of California, Los Angeles Lung Structure and Function Airway Epithelial
More informationEXAMPLE. - Potentially responsive to PI3K/mTOR and MEK combination therapy or mtor/mek and PKC combination therapy. ratio (%)
Dr Kate Goodhealth Goodhealth Medical Clinic 123 Address Road SUBURBTOWN NSW 2000 Melanie Citizen Referring Doctor Your ref Address Dr John Medico 123 Main Street, SUBURBTOWN NSW 2000 Phone 02 9999 9999
More informationMEK1 Assay Kit 1 Catalog # Lot # 16875
MEK1 Assay Kit 1 Kit Components Assay Dilution Buffer (ADB), Catalog # 20-108. Three vials, each containing 1.0ml of assay dilution buffer (20mM MOPS, ph 7.2, 25mM ß-glycerol phosphate, 5mM EGTA, 1mM sodium
More informationDevelopment of important genes during breast carcinogenesis
Nagoya Med. J., 107 Development of important genes during breast carcinogenesis AYA NAIKI-ITO Department of experimental pathology and tumor biology Nagoya City University Graduate School of Medical Sciences
More informationClinical Significance of BRAF Gene Mutations in Patients with Non-small Cell Lung Cancer
Clinical Significance of BRAF Gene Mutations in Patients with Non-small Cell Lung Cancer MASASHI KOBAYASHI 1, MAKOTO SONOBE 1, TSUYOSHI TAKAHASHI 1, AKIHIKO YOSHIZAWA 2, MASASHI ISHIKAWA 1, RYUTARO KIKUCHI
More informationAnnexure III SOLUTIONS AND REAGENTS
Annexure III SOLUTIONS AND REAGENTS A. STOCK SOLUTIONS FOR DNA ISOLATION 0.5M Ethylene-diamine tetra acetic acid (EDTA) (ph=8.0) 1M Tris-Cl (ph=8.0) 5M NaCl solution Red cell lysis buffer (10X) White cell
More informationProtein MultiColor Stable, Low Range
Product Name: DynaMarker Protein MultiColor Stable, Low Range Code No: DM670L Lot No: ******* Size: 200 μl x 3 (DM670 x 3) (120 mini-gel lanes) Storage: 4 C Stability: 12 months at 4 C Storage Buffer:
More informationAmoyDx TM BRAF V600E Mutation Detection Kit
AmoyDx TM BRAF V600E Mutation Detection Kit Detection of V600E mutation in the BRAF oncogene Instructions For Use Instructions Version: B3.1 Date of Revision: April 2012 Store at -20±2 o C 1/5 Background
More informationPositive response to Icotinib in metastatic lung adenocarcinoma with acquiring EGFR Leu792H mutation after AZD9291 treatment: a case report
Wang and Chen BMC Cancer (2019) 19:131 https://doi.org/10.1186/s12885-019-5352-7 CASE REPORT Open Access Positive response to Icotinib in metastatic lung adenocarcinoma with acquiring EGFR Leu792H mutation
More informationDevelopment of Carcinoma Pathways
The Construction of Genetic Pathway to Colorectal Cancer Moriah Wright, MD Clinical Fellow in Colorectal Surgery Creighton University School of Medicine Management of Colon and Diseases February 23, 2019
More informationNGS in tissue and liquid biopsy
NGS in tissue and liquid biopsy Ana Vivancos, PhD Referencias So, why NGS in the clinics? 2000 Sanger Sequencing (1977-) 2016 NGS (2006-) ABIPrism (Applied Biosystems) Up to 2304 per day (96 sequences
More informationSupporting Information
Supporting Information Franco et al. 10.1073/pnas.1015557108 SI Materials and Methods Drug Administration. PD352901 was dissolved in 0.5% (wt/vol) hydroxyl-propyl-methylcellulose, 0.2% (vol/vol) Tween
More informationBRAF: dal melanoma alla HCL
ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI FONDAZIONE G. Pascale NAPOLI SC Biologia Cellulare e Bioterapie CENTRO RICERCHE ONCOLOGICHE MERCOGLIANO (AV) Laboratorio di Farmacogenomica BRAF: dal
More informationExpression profile of tumor suppressor gene RASSF1 in lacrimal gland carcinoma
Expression profile of tumor suppressor gene RASSF1 in lacrimal gland carcinoma C.H. Zeng, B. Guo, J. Chen, W.M. He and Q.L. Luo Ophthalmology Department of West China Hospital, Sichuan University, Sichuan,
More informationThe mutations that drive cancer. Paul Edwards. Department of Pathology and Cancer Research UK Cambridge Institute, University of Cambridge
The mutations that drive cancer Paul Edwards Department of Pathology and Cancer Research UK Cambridge Institute, University of Cambridge Previously on Cancer... hereditary predisposition Normal Cell Slightly
More informationEGFR Antibody. Necitumumab, LY , IMC-11F8. Drug Discovery Platform: Cancer Cell Signaling
EGFR Antibody Necitumumab, LY3012211, IMC-11F8 Derived from Yarden Y and Shilo BZ 1 ; Schneider MR and Wolf E. 2 Drug Discovery Platform: Cancer Cell Signaling A Single-Arm, Multicenter, Open-Label, Phase
More informationProtein Domain-Centric Approach to Study Cancer Somatic Mutations from High-throughput Sequencing Studies
Protein Domain-Centric Approach to Study Cancer Somatic Mutations from High-throughput Sequencing Studies Dr. Maricel G. Kann Assistant Professor Dept of Biological Sciences UMBC 2 The term protein domain
More informationCancer. The fundamental defect is. unregulated cell division. Properties of Cancerous Cells. Causes of Cancer. Altered growth and proliferation
Cancer The fundamental defect is unregulated cell division. Properties of Cancerous Cells Altered growth and proliferation Loss of growth factor dependence Loss of contact inhibition Immortalization Alterated
More informationFluxion Biosciences and Swift Biosciences Somatic variant detection from liquid biopsy samples using targeted NGS
APPLICATION NOTE Fluxion Biosciences and Swift Biosciences OVERVIEW This application note describes a robust method for detecting somatic mutations from liquid biopsy samples by combining circulating tumor
More informationCONTRACTING ORGANIZATION: Rush University Medical Center Chicago, IL 60612
AD Award Number: W81XWH-11-1-0302 TITLE: Yin and Yang of Heparanase in breast Tumor Initiation PRINCIPAL INVESTIGATOR: Xiulong Xu, Ph.D. CONTRACTING ORGANIZATION: Rush University Medical Center Chicago,
More informationOverexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma
Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma The Harvard community has made this article openly available. Please share
More informationNext generation diagnostics Bringing high-throughput sequencing into clinical application
Next generation diagnostics Bringing high-throughput sequencing into clinical application Leonardo A. Meza-Zepeda, PhD Translational Genomics Group Institute for Cancer Research Leonardo.Meza-Zepeda@rr-research.no
More informationMolecular biomarker profile of EGFR copy number, KRAS and BRAF mutations in colorectal carcinoma
ORIGINAL ARTICLE Molecular biomarker profile of EGFR copy number, KRAS and BRAF mutations in colorectal carcinoma Rong Rong, Jamie Tull, Shengle Zhang Department of Pathology, SUNY Upstate University,
More informationCLINICAL UPDATE ON K-RAS
CLINICAL UPDATE ON K-RAS TARGETED THERAPY IN GASTROINTESTINAL CANCERS S. PA N T, 1 J. H U B B A R D, 2 E. M A RT I N E L L I, 3 A N D T. B E K A I I - S A A B 4 SELECTED HIGHLIGHTS 1 Department of Investigational
More informationThe PI3K/AKT axis. Dr. Lucio Crinò Medical Oncology Division Azienda Ospedaliera-Perugia. Introduction
The PI3K/AKT axis Dr. Lucio Crinò Medical Oncology Division Azienda Ospedaliera-Perugia Introduction Phosphoinositide 3-kinase (PI3K) pathway are a family of lipid kinases discovered in 1980s. They have
More informationIdentification of Novel Variant of EML4-ALK Fusion Gene in NSCLC: Potential Benefits of the RT-PCR Method
International journal of Biomedical science ORIGINAL ARTICLE Identification of Novel Variant of EML4-ALK Fusion Gene in NSCLC: Potential Benefits of the RT-PCR Method Martin K. H. Maus 1, 2, Craig Stephens
More informationNew: P077 BRCA2. This new probemix can be used to confirm results obtained with P045 BRCA2 probemix.
SALSA MLPA KIT P045-B2 BRCA2/CHEK2 Lot 0410, 0609. As compared to version B1, four reference probes have been replaced and extra control fragments at 100 and 105 nt (X/Y specific) have been included. New:
More informationIntelliGENSM. Integrated Oncology is making next generation sequencing faster and more accessible to the oncology community.
IntelliGENSM Integrated Oncology is making next generation sequencing faster and more accessible to the oncology community. NGS TRANSFORMS GENOMIC TESTING Background Cancers may emerge as a result of somatically
More informationElectrical Stimulation Control Nerve Regeneration via the p38 Mitogen-activated Protein Kinase and CREB
Electrical Stimulation Control Nerve Regeneration via the p38 Mitogen-activated Protein Kinase and CREB Kenji Kawamura, Yoshio Kano. Kibi International University, Takahashi-city, Japan. Disclosures: K.
More informationRapid BRAF mutation detection in melanoma patients by immunohistochemistry
http://dx.doi.org/10.17202/juso.2017.4.1 Journal of Universal Science Vol 4(1): 1-5, 2017 Rapid BRAF mutation detection in melanoma patients by immunohistochemistry László FÜLÖP 1, Katalin GÖTZER 1, Erzsébet
More informationDescription of Procedure or Service. Policy. Benefits Application
Corporate Medical Policy KRAS, NRAS, BRAF Mutation Analysis and Related File Name: Origination: Last CAP Review: Next CAP Review: Last Review: kras_nras_braf_mutation_analysis_and_related_treatment_in_metastatic_colorectal_cancer
More informationRefining Prognosis of Early Stage Lung Cancer by Molecular Features (Part 2): Early Steps in Molecularly Defined Prognosis
5/17/13 Refining Prognosis of Early Stage Lung Cancer by Molecular Features (Part 2): Early Steps in Molecularly Defined Prognosis Johannes Kratz, MD Post-doctoral Fellow, Thoracic Oncology Laboratory
More informationEvolution of Pathology
1 Traditional pathology Molecular pathology 2 Evolution of Pathology Gross Pathology Cellular Pathology Morphologic Pathology Molecular/Predictive Pathology Antonio Benivieni (1443-1502): First autopsy
More informationNEW FRONTIERS IN THE BIOLOGY OF LUNG CANCER: WHAT INFLUENCES DIAGNOSIS AND THERAPY?
NEW FRONTIERS IN THE BIOLOGY OF LUNG CANCER: WHAT INFLUENCES DIAGNOSIS AND THERAPY? STEVEN M. DUBINETT, MD CHIEF OF THE DIVISION OF PULMONARY AND CRITICAL CARE MEDICINE DIRECTOR, UCLA LUNG CANCER PROGRAM
More informationIntroduction: 年 Fas signal-mediated apoptosis. PI3K/Akt
Fas-ligand (CD95-L; Fas-L) Fas (CD95) Fas (apoptosis) 年 了 不 度 Fas Fas-L 力 不 Fas/Fas-L T IL-10Fas/Fas-L 不 年 Fas signal-mediated apoptosis 度降 不 不 力 U-118, HeLa, A549, Huh-7 MCF-7, HepG2. PI3K/Akt FasPI3K/Akt
More informationThe Pathology of Neoplasia Part II
The Pathology of Neoplasia Part II February 2018 PAUL BOGNER, MD A S S O C I A T E P R O F E S S O R O F O N C O L O G Y P A T H O L O G Y A N D D E R M A T O L O G Y Clinical goals of cancer pathology
More informationLiquid biopsy in lung cancer: The EGFR paradigm
Liquid biopsy in lung cancer: The EGFR paradigm Lynette M. Sholl, M.D. Brigham and Women s Hospital Dana Farber Cancer Institute Department of Pathology Boston, MA Disclosure of Relevant Financial Relationships
More informationBersagli molecolari nel melanoma
Bersagli molecolari nel melanoma Giuseppe Palmieri - Unit of Cancer Genetics Institute of Biomolecular Chemistry, CNR, Sassari Essential alterations in malignant cells Hanahan & Weinberg, Cell 2000 Essential
More informationMolecular Testing in Lung Cancer
Molecular Testing in Lung Cancer Pimpin Incharoen, M.D. Assistant Professor, Thoracic Pathology Department of Pathology, Ramathibodi Hospital Genetic alterations in lung cancer Source: Khono et al, Trans
More informationPushing the boundaries-targeted therapies
Pushing the boundaries-targeted therapies Professor Grant McArthur MB BS PhD Director Melanoma and Skin Cancer VCCC Parkville, Peter MacCallum Cancer Centre Lorenzo Galli Chair of Melanoma & Skin Cancers,
More informationFOR REVIEW. BMB Reports - Manuscript Submission. Manuscript Draft. Manuscript Number: BMB
BMB Reports - Manuscript Submission Manuscript Draft Manuscript Number: BMB-18-095 Title: Insulin Receptor Substrate 2:A Bridge between Hippo and AKT Pathways Article Type: Perspective (Invited Only) Keywords:
More informationVIRUSES AND CANCER Michael Lea
VIRUSES AND CANCER 2010 Michael Lea VIRAL ONCOLOGY - LECTURE OUTLINE 1. Historical Review 2. Viruses Associated with Cancer 3. RNA Tumor Viruses 4. DNA Tumor Viruses HISTORICAL REVIEW Historical Review
More informationDiagnostic test Suggested website label Description Hospitals available
Diagnostic test Suggested website label Description Hospitals available Abbott Molecular Inc, PATHVYSION HER-2 DNA Probe Kit (FISH) PathVysion kit A diagnostic tool used to determine whether a particular
More informationGeneral Laboratory methods Plasma analysis: Gene Expression Analysis: Immunoblot analysis: Immunohistochemistry:
General Laboratory methods Plasma analysis: Plasma insulin (Mercodia, Sweden), leptin (duoset, R&D Systems Europe, Abingdon, United Kingdom), IL-6, TNFα and adiponectin levels (Quantikine kits, R&D Systems
More informationSUPPLEMENTARY INFORMATION
doi:10.1038/nature23291 Supplementary discussion part 1 Our model suggests that, in tumours that express Class 3 BRAF mutants and activated RAS, both BRAF MUT /RAF WT heterodimers and WT RAF dimers are
More informationGENETIC ANALYSIS OF RAS SIGNALING PATHWAYS IN CELL PROLIFERATION, MIGRATION AND SURVIVAL
Manuscript EMBO-2009-72496 GENETIC ANALYSIS OF RAS SIGNALING PATHWAYS IN CELL PROLIFERATION, MIGRATION AND SURVIVAL Matthias Drosten, Alma Dhawahir, Eleanor Sum, Jelena Urosevic, Carmen Lechuga, Luis Esteban,
More informationUpdate on Genetic Testing for Melanoma
Update on Genetic Testing for Melanoma Emily Y. Chu, M.D., Ph.D. Assistant Professor of Dermatology & Pathology and Laboratory Medicine Hospital of the University of Pennsylvania February 18, 2018 AAD
More informationp53 and Apoptosis: Master Guardian and Executioner Part 2
p53 and Apoptosis: Master Guardian and Executioner Part 2 p14arf in human cells is a antagonist of Mdm2. The expression of ARF causes a rapid increase in p53 levels, so what would you suggest?.. The enemy
More information